WO2006016110A1 - Methods and kit for the prognosis of breast cancer - Google Patents
Methods and kit for the prognosis of breast cancer Download PDFInfo
- Publication number
- WO2006016110A1 WO2006016110A1 PCT/GB2005/002971 GB2005002971W WO2006016110A1 WO 2006016110 A1 WO2006016110 A1 WO 2006016110A1 GB 2005002971 W GB2005002971 W GB 2005002971W WO 2006016110 A1 WO2006016110 A1 WO 2006016110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression
- markers
- genes
- level
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Definitions
- the present invention relates to a method and kit, including parts thereof, for the prognosis of breast cancer.
- the method involves identifying a gene expression pattern that indicates the likelihood of survival of a patient with breast cancer and/or likelihood of recurrence of the disease and/or the metastatic character of the cancer in a patient being treated, or having been treated, for breast cancer.
- Breast cancer is the most common female cancer in the UK, US and Denmark. It is also the most common form of cancer affecting women in the industrialised world. The incidence of breast cancer has been gradually increasing, and in the US, it is the second most common cause of death due to cancer. Indeed, in 1997, it was estimated that 181 ,000 new cases were reported in the US, and it has been estimated that 40,000 people die of breast cancer every year. Despite the global efforts that have been made to combat this condition, there has been very little change in the incidence of breast cancer, although early detection and new therapies have marginally improved survival over the past few decades.
- the prognosis of the disease is important because it determines the treatment that will be given. Accurate prognosis could allow the oncologist to, for example, favour the administration of hormone therapy or chemotherapy and recommend surgery only in the most aggressive cases of cancer.
- WO 02/103320 discloses thousands of genetic markers whose expression is correlated with clinical prognosis, and which can be used to distinguish patients having good prognoses from poor prognoses.
- the method for determining expression involves comparing the expression pattern of a test sample of tissue taken from a patient with that of a sample of tissue taken from a patient with a good prognosis and also with that of a sample taken from a patient with a known poor prognosis, and determining which of these samples the test sample most closely corresponds to.
- the second component therefore indicates the likelihood of incidence free survival of a patient presenting with breast cancer and the third component indicates the aggressive nature of the disease.
- Each molecular signature comprises a plurality of genetic markers whose expression, either high or low in respect of tissue from a patient with moderate prognosis (see hereinafter), is indicative of a given outcome.
- we have analysed each molecular signature in order to identify which genetic markers are the best indicators of the outcome of a given disease, in other words those that contribute most to the predictive ability of the molecular signature. This subset of markers is known, collectively, as the refined molecular signature.
- a first molecular signature which comprises two sets of molecular markers whose high expression correlates with low survival rate; the first set comprises those molecular markers that are the most statistically significant indicators of low survival rate, these are referred to herein, collectively, as the first primary molecular signature [Set (A)]: AMF, ATF4, Cyr61 , ER, Matriptase2, MET, MLN64, MMP7, Nectin4, PAR1A, Psoriason, Pttgi , Rho-C, Scotin, SDF1 , SEMP1 , SPF45, SST1, ST15, TACC2,
- EHMS EHMS, FAK, FAP, GIRK, HAVR1 , Isotopo3, JAK1 , LOX12, NET-2, PAR1A2, PTHrP, Rho-G, S100A4, SPARC, TCF3, VECAD, Vilip, Wave2.
- NPI (low) is ⁇ 3.4 and 86% of patients survive 15 years
- NPI (moderate) is 3.4 - 5.4 and 42% of patients survive 15 years
- NPI (high) is >5.4 and 13% of patients survive 15 years.
- a second molecular signature which comprises two sets of molecular markers whose low expression correlates with low survival rate; the first set comprises those molecular markers that are the most statistically significant indicators of low survival rate, these are referred to herein, collectively, as the second primary molecular signature [Set (C)]: ARP2, Atf-3, HuR 1 MEN1, Paracellin, PTP-RK Radixin, RHO8/gdiG-Ratio; and the second set comprises the afore plus at least one of the following molecular markers, referred to herein, collectively, as the second secondary molecular signature [Set (D)]: aMOT, Atf-1, Claudin-1, IL22R, Rock 2 Veg1.
- a third molecular signature which comprises two sets of molecular markers whose high expression correlates with a low incidence of cancer free survival; the first set comprises those molecular markers that are the most statistically significant indicators of a low incidence of cancer free survival, these are referred to herein, collectively, as the third primary molecular signature [Set (E)]:
- a fourth molecular signature which comprises two sets of molecular markers whose low expression correlates with a low incidence of cancer free survival; the first set comprises those molecular markers that are the most statistically significant indicators of a low incidence of cancer free survival, these are referred to herein, collectively, as the fourth primary molecular signature [Set (G)]:
- a fifth molecular signature which comprises two sets of molecular markers whose high expression correlates with metastatic cancer; the first set comprises those molecular markers that are the most statistically significant indicators of a metastatic cancer, these are referred to herein, collectively, as the fifth primary molecular signature [Set (I)]: BAF57. BNDF, CAR1 , CASM, Cathepsin-L, Creb1/2, CXCR10, DRIM 1 HERG 7 IL7R, tL-11, Kissi , MKK1, PMN-elastase, PTTP1, SDF5, TACC2. Ubiquitin, VIPR1, VUDP; and the second set comprises the afore plus at least one of the following molecular markers referred to herein, collectively, as the fifth secondary molecular signature [Set (J)]:
- a sixth molecular signature which comprises two sets of molecular markers whose low expression correlates with metastatic cancer; the first set comprises those molecular markers that are the most statistically significant indicators of a metastatic cancer, these are referred to herein, collectively, as the sixth primary molecular signature [Set (K)]:
- the second set comprises the afore plus at least one of the following molecular markers referred to herein, collectively, as the sixth secondary molecular signature [Set (L)]: ALCAM, Eplin, ERbeta, Glypic3, JAK1 , MAGI-1 , PEDF, PKC-eta, Stathlin,
- a method for determining the prognosis of mammalian breast cancer which method comprises:
- said methodology in part (a) thereof, additionally comprises determining the expression level of genes encoding at least one molecular marker in Set (B), in order to determine whether these genes have a high level of expression; and/or the expression level of genes encoding the molecular markers in Set (C), in order to determine whether these genes are under expressed; and/or determining the expression level of genes encoding at least one molecular marker in Set (D), in order to determine whether these genes are under expressed and, if the above expression patterns are identified, concluding that the individual has a low likelihood of survival.
- a method for determining the prognosis of mammalian breast cancer which method comprises:
- said methodology in part (a) thereof, additionally, or alternatively, comprises determining the expression level of genes encoding at least one molecular marker in Set (D) in order to determine whether these genes are under expressed and, if they are, concluding that the individual has a low likelihood of survival.
- said methodology in part (a) thereof, additionally comprises determining the expression level of genes in Set (A) and/or at least one gene in Set (B) in order to determine if these genes are over expressed and, if they are, concluding that the individual has a low likelihood of survival.
- a method for determining the prognosis of mammalian breast cancer which method comprises:
- the methodology additionally comprises, in part (a) thereof, determining the expression level of genes encoding at least one molecular marker in Set (F), in order to determine whether these genes have a high level of expression; and/or determining the expression level of genes encoding the molecular markers in Set (G) 1 in order to determine whether these genes are under expressed; and/or determining the expression level of genes encoding at least one molecular marker in Set (H), in order to determine whether these genes are under expressed, and if the above expression patterns are identified, concluding that the individual has a high likelihood of cancer recurrence.
- a method for determining the prognosis of mammalian breast cancer which method comprises:
- said methodology in part (a) thereof, additionally, or alternatively, comprises determining the expression level of genes encoding at least one molecular marker in Set (H), in order to determine whether these genes are under expressed and, if they are, concluding that the individual has a high likelihood of cancer recurrence.
- said methodology in part (a) thereof, additionally comprises determining the expression level of genes in Set (E) and/or at least one gene in Set (F) in order to determine if these genes are over expressed and, if they are, concluding that the individual has a high likelihood of cancer recurrence.
- a method for determining the prognosis of mammalian breast cancer which method comprises:
- the methodology additionally comprises, in part (a) thereof, determining the expression level of genes encoding at least one molecular marker in Set (J), in order to determine whether these genes have a high level of expression; and/or determining the expression level of the gene encoding the molecular marker in Set (K), in order to determine whether this gene is under expressed; and/or determining the expression level of genes encoding at least one molecular marker in Set (L), in order to determine whether these genes are under expressed and, if the above expression patterns are identified, concluding that the individual has a metastatic form of cancer.
- a method for determining the prognosis of mammalian breast cancer which method comprises:
- said methodology in part (a) thereof, additionally, or alternatively, comprises determining the expression level of genes encoding at least one molecular marker in Set (L) in order to determine whether these genes are under expressed and, if they are, concluding that the individual has a metastatic form of cancer.
- said methodology in part (a) thereof, additionally comprises determining the expression level of genes in Set (I) and/or at least one molecular marker in Set (J) in order to determine if these genes are over expressed and, if they are, concluding that the individual has a metastatic form of cancer.
- said methodology in part (a) thereof, additionally comprises determining the expression level of genes in Set (I) and/or at least one molecular marker in Set (J) in order to determine if these genes are over expressed and, if they are, concluding that the individual has a metastatic form of cancer.
- the assay is, ideally, undertaken for human breast cancer tissue and, more preferably still, female human breast cancer tissue.
- the sample of tissue that is examined is assayed for the presence of RNA, preferably total RNA and, more preferably still, the amount of mRNA. It will be apparent to those skilled in the art that techniques available for measuring RNA content are well known and, indeed, routinely practised by those in the clinical diagnostics field.
- the method involves assaying for the protein encoded by each of the molecular markers and so, typically, but not exclusively, involves the use of agents that bind to the relevant proteins and so identify same.
- agents are antibodies and, most ideally, monoclonal antibodies which, advantageously, have been labelled with a suitable tag whereby the existence of the bound antibody can be determined.
- Assay techniques for identifying proteins are well known to those skilled in the art and indeed used every day by workers in the field of clinical diagnostics.
- the methodology of the invention may involve the amplification of a selected marker prior to the identification of same and in this case, typically, amplification will be undertaken using a PCR reaction wherein oligonucleotide probes specific for the molecular marker of interest are used in order to amplify same prior to determining the presence and, having regard to the degree of amplification, the amount thereof.
- the level of expression of a given molecular marker is determined having regard to a control sample, wherein the control sample is a sample of breast tissue which is cancer free or from a patient with a moderate prognosis as hereindefined. More ideally still this sample of breast tissue is taken from an individual who is not presenting with the disease. Alternatively still, the control is a recognised standard for expression of each relevant gene in a healthy individual.
- the level of gene expression may be measured by real-time quantitative PCR, using a method disclosed in Jiang et al 2003a or Parr and Jiang 2004.
- the likelihood of survival means the likelihood that the patient will be alive for the next 10 years.
- the likelihood of recurrence means the likelihood that the cancer will recur within 10 years.
- a metastatic form of cancer means that the cancer will have spread from the organ or tissue of origin to another part of the body.
- kit for performing any one or more of the aforementioned methods wherein said kit comprises:
- kits for determining the prognosis of mammalian breast cancer which comprises:
- said kit additionally comprises: (a) a plurality of probes for identifying: at least one transcript of each of the genes in Set (C), and/or at least one transcript for at least one of the genes in Set (B) or (D), and;
- kits for determining the prognosis of mammalian breast cancer which comprises: (a) a plurality of probes for identifying at least one transcript of each of the genes in Set (E), and; (b) optionally, reagents and instructions that determine, or show how to determine, the level of expression of each of said genes.
- said kit additionally comprises:
- kits for determining the prognosis of mammalian breast cancer which comprises:
- kit additionally comprises:
- kits comprising any selected combination of the aforementioned sets of probes for identifying the aforementioned sets of molecular markers.
- a microarray comprising any one or more of the aforementioned sets of probes for identifying the level of expression of any one or more of the aforementioned sets of molecular markers.
- a kit for determining the likelihood of survival and/or recurrence of breast cancer and/or metastatic nature of a cancer in a patient comprises:
- a second microarray comprising a plurality of probes for identifying the same set of molecular markers in an internal standard that represents the normal level of expression of said markers.
- the invention also provides a microarray or set of probes as described above.
- Figure 1 shows a Kaplan-Meier survival curve for all the markers in Table
- Figure 2 shows a Kaplan-Meier survival curve for markers indicated with a * in Table 1.
- Figure 3 shows a Kaplan-Meier survival curve for all the markers in Table 2.
- Figure 4 shows a Kaplan-Meier survival curve for markers indicated with a * in Table 2.
- MRC-5 were purchased from the European Collection of Animal Cell Cultures
- Mammary tissues were frozen sectioned. Sections were divided into the following three parts: one portion for routine histology, one portion for immunohistochemistry and the other portion was for preparation of RNA.
- RNA extraction kit and RT kit were obtained from AbGene Ltd, Surrey, England, UK.
- PCR primers were designed using Beacon Designer (California, USA) and synthesised by InvitrogenTM Ltd (Paisley, Scotland, UK). Molecular biology grade agarose and DNA ladder were from Invitrogen. Mastermix for routine PCR and quantitative PCR was from AbGene.
- the transcript level of the CCN family members from the above-prepared cDNA was determined using a real-time quantitative PCR, based on the AmplifuorTM technology (Nazarenko et al 1997), modified from a method previous reported (Jiang et al 2003a and 2003b). Briefly, a pair of PCR primers were designed using the Beacon Designer software (version 2, California, USA). To one of the primers (routinely to the antisense primer in our laboratory), an additional sequence, known as the Z sequence (5' actgaacctgaccgtaca'3) which is complementary to the universal Z probe (Nazarenko et at 1997) (Intergen Inc., England, UK), was added. A TaqmanTM detection kit for ⁇ -actin was purchased from Perkin-ElmerTM.
- the reaction was carried out using the following: Hot-start Q-master mix (Abgene), IOpmol of specific forward primer, 1pmol reverse primer which has the Z sequence, IOpmol of FAM-tagged probe (Intergen Inc.), and cDNA from approximate 50ng RNA (calculated from the starting RNA in the RT reaction).
- the reaction was carried out using IcyclerlQTM (Bio-RadTM) which is equipped with an optic unit that allows real time detection of 96 reactions, using the following condition: 94°C for 12 minutes, 50 cycles of 94°C for 15 seconds, 55 0 C for 40 seconds and 72°C for 20 seconds (Jiang et al 2003b, 2003c, Parr and Jiang 2004).
- the levels of the transcripts were generated from an internal standard (Jiang et al 2003a) that was simultaneously amplified with the samples. The results are shown here in two ways: levels of transcripts based on equal amounts of RNA, or as a target/CK19 ratio.
- Frozen sections of breast tumour and background tissue were cut at a thickness of 6 ⁇ m using a cryostat (Jiang ⁇ t al 2003c). The sections were mounted on super frost plus microscope slides, air dried and then fixed in a mixture of 50% acetone and 50% methanol. The sections were then placed in "Optimax" wash buffer for 5-10 minutes to rehydrate. Sections were incubated for 20 mins in a 0.6% BSA blocking solution and probed with a primary antibody. Following extensive washings, sections were incubated for 30 minutes in a secondary biotinylated antibody (Multilink Swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc.).
- a secondary biotinylated antibody Multilink Swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc.
- Figure 1 shows that 92.2% of individuals having what is termed herein as a "good signature” (that is not having a high expression of the molecules in the left-hand column of Table 1 , and not having under expression of the molecules in the right-hand column of Table 1), are predicted to survive for up to 148.9 months, while only 8.3% of individuals having what is termed herein as a "bad signature” (that is having a high expression of the molecules in the left-hand column of
- Table 1 and under expression of the molecules in the right-hand column of Table 1) are predicted to survive for up to 40 months. This result is statistically significant, with a p value ⁇ 0.00001.
- Figure 4 shows the predicted survival curve using the third primary and fourth primary molecular signature, with 91.7% of individuals having a good signature predicted to have no recurrence of the disease for up to 148.4 months, and only 5.88% of individuals having a bad signature predicted to survive, without any recurrence of the disease, for up to 44.2 months (p ⁇ 0.000001).
- HGF/SF inhibited growth of breast tumour, induced by fibroblasts.
- Nazarenko et al 1997 Nazarenko IA, Bhatnagar SK, Hohman RJ. A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic
- Parr and Jiang 2004 Parr C and Jiang WG.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05763127A EP1781814B3 (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer |
CA002576113A CA2576113A1 (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer |
DE602005018789T DE602005018789D1 (en) | 2004-08-10 | 2005-07-27 | METHOD AND KIT FOR THE PROGNOSIS OF BREAST CANCER |
MX2007001640A MX2007001640A (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer. |
US11/573,487 US20100035240A1 (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer |
CN2005800303728A CN101014720B (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer |
DK05763127.7T DK1781814T3 (en) | 2004-08-10 | 2005-07-27 | Methods and kits for breast cancer prognosis |
AT05763127T ATE454474T1 (en) | 2004-08-10 | 2005-07-27 | METHOD AND KIT FOR PROGNOSIS OF BREAST CANCER |
AU2005271113A AU2005271113B2 (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer |
JP2007525333A JP5117852B2 (en) | 2004-08-10 | 2005-07-27 | Prognosis method and kit for breast cancer |
GB0701676A GB2430741A (en) | 2004-08-10 | 2007-01-30 | Methods and Kit for the Prognosis of Breast Cancer |
HK07111076.7A HK1103422A1 (en) | 2004-08-10 | 2007-10-12 | Methods and kit for the prognosis of breast cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0417740.8 | 2004-08-10 | ||
GB0417740A GB0417740D0 (en) | 2004-08-10 | 2004-08-10 | Methods and kit for the prognosis of breast cancer |
GB0426777A GB0426777D0 (en) | 2004-12-07 | 2004-12-07 | Methods and kit for the prognosis of breast cancer |
GB0426777.9 | 2004-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006016110A1 true WO2006016110A1 (en) | 2006-02-16 |
WO2006016110A8 WO2006016110A8 (en) | 2006-08-24 |
Family
ID=35044601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/002971 WO2006016110A1 (en) | 2004-08-10 | 2005-07-27 | Methods and kit for the prognosis of breast cancer |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100035240A1 (en) |
EP (1) | EP1781814B3 (en) |
JP (2) | JP5117852B2 (en) |
CN (1) | CN102443627B (en) |
AT (1) | ATE454474T1 (en) |
AU (1) | AU2005271113B2 (en) |
CA (1) | CA2576113A1 (en) |
DE (1) | DE602005018789D1 (en) |
DK (1) | DK1781814T3 (en) |
ES (1) | ES2339132T7 (en) |
GB (1) | GB2430741A (en) |
HK (1) | HK1103422A1 (en) |
MX (1) | MX2007001640A (en) |
PT (1) | PT1781814E (en) |
WO (1) | WO2006016110A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008138868A2 (en) * | 2007-05-09 | 2008-11-20 | Traslational Cancer Drugs Pharma, S.L. | In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression |
WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
JP2009543044A (en) * | 2006-07-07 | 2009-12-03 | ヒュン−キ・キム | Breast cancer prognostic marker comprising HCCR-1 and obesity-inducing composition |
JP2010505123A (en) * | 2006-09-29 | 2010-02-18 | トランスレーショナル セラピューティクス,インク. | eIF4E regulon-based diagnostics |
US20100081666A1 (en) * | 2008-07-14 | 2010-04-01 | Wyeth | Src activation for determining cancer prognosis and as a target for cancer therapy |
WO2010054379A2 (en) * | 2008-11-10 | 2010-05-14 | The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
WO2010063454A1 (en) * | 2008-12-01 | 2010-06-10 | University Of Ulster | Method of stratifying breast cancer patients based on gene expression |
CN1919874B (en) * | 2006-09-18 | 2010-09-08 | 中国人民解放军军事医学科学院生物工程研究所 | Antibody molecule ATF-Fc fusion albumen of antiurokinase type fibrinolysin activator receptor and use thereof |
US20120183543A1 (en) * | 2009-05-08 | 2012-07-19 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
WO2013110053A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
US8497292B2 (en) | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
EP2723924A1 (en) * | 2011-06-22 | 2014-04-30 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
CN104725487A (en) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | Tight junction protein inhibitor polypeptide and application thereof |
CN104725488A (en) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | Tight junction protein inhibitor polypeptide and application thereof |
EP2751570A4 (en) * | 2011-08-31 | 2015-08-12 | Oncocyte Corp | Methods and compositions for the treatment and diagnosis of cancer |
EP3093343A4 (en) * | 2014-01-10 | 2017-12-27 | Juntendo Educational Foundation | Method for assessing lymph node metastatic potential of endometrial cancer |
US10047155B2 (en) | 2015-06-05 | 2018-08-14 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor |
CN108504726A (en) * | 2018-03-28 | 2018-09-07 | 华南农业大学 | The pretreated methods of PCR are carried out using AMF single spore minim DNAs |
EP3321683A4 (en) * | 2015-07-09 | 2018-11-21 | Juntendo Educational Foundation | Method for evaluating lymph node metastatic potential of endometrial cancer |
CN109620832A (en) * | 2019-01-14 | 2019-04-16 | 大连大学 | Glycocholic acid is preparing the application in resisting hyperplasia of mammary glands drug |
WO2020008097A3 (en) * | 2018-07-03 | 2020-03-19 | Universidad De Granada | Method for obtaining data that can be used for the prediction or prognosis of overall survival and relapse-free survival from cancer, and composition that can modulate the activity of atf4 for the treatment of cancer |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338843B1 (en) * | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | GENOMIC FOOTPRINT OF CANCER OF MAMA. |
KR101421326B1 (en) * | 2010-03-30 | 2014-07-21 | 서울대학교산학협력단 | Composition for predicting prognosis of breast cancer and kit comprising the same |
CN103562723B (en) * | 2011-03-27 | 2017-04-26 | 欧恩克斯特姆诊断学(毛里求斯)私人有限公司 | Markers for identifying tumor cells, methods and kit thereof |
FR2988479B1 (en) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | METHOD FOR DETERMINING THE SUSCEPTIBILITY TO NOSOCOMIAL INFECTIONS |
KR101672531B1 (en) * | 2013-04-18 | 2016-11-17 | 주식회사 젠큐릭스 | Genetic markers for prognosing or predicting early stage breast cancer and uses thereof |
CN103235141A (en) * | 2013-04-27 | 2013-08-07 | 上海交通大学医学院附属新华医院 | Application of ATF (activating transcription factor) 3 to predicting bladder cancer metastasis and judging prognosis |
KR101548830B1 (en) | 2013-12-30 | 2015-08-31 | 가천대학교 산학협력단 | Cmposition for predicting breast cancer prognosis using marker for breast cancer stem cell screened by culture method of stem cell |
LT3137595T (en) * | 2014-04-29 | 2019-06-25 | Novartis Ag | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
CN105986024B (en) * | 2015-02-27 | 2019-10-25 | 复旦大学附属肿瘤医院 | One group of gene and its application for triple negative breast cancer prognosis |
CN106295244B (en) * | 2015-06-05 | 2019-09-17 | 上海交通大学医学院附属瑞金医院 | The screening technique of diagnosing tumor marker, the breast cancer Lung metastases related gene obtained in this way and its application |
CN106337081B (en) * | 2016-02-02 | 2020-01-21 | 中国医学科学院肿瘤医院 | Correlation of SNP locus rs1054135 of FABP4 gene and triple negative breast cancer prognosis |
WO2018074865A2 (en) * | 2016-10-21 | 2018-04-26 | 서울대학교병원 | Composition and method for breast cancer prognosis prediction |
EP3364190A1 (en) * | 2017-02-20 | 2018-08-22 | Panka Cancer Research AG | Method of detecting cancer or cancer cells |
TW201834698A (en) * | 2017-03-03 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | Antibody-drug conjugate of anti-IL-7R antibody, and pharmaceutical composition for treating cancer or inflammation and containing antibody-drug conjugate of anti-IL-7R antibody and cytotoxic drug |
KR102280672B1 (en) * | 2019-12-20 | 2021-07-23 | 주식회사 베르티스 | A Composition for Diagnosing Cancer |
CN114758773A (en) * | 2022-05-25 | 2022-07-15 | 四川大学华西医院 | Bladder cancer immunotherapy biomarker, immune risk model and application of immune risk model |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5872217A (en) * | 1989-01-17 | 1999-02-16 | The Johns Hopkins University | Antibodies which specifically bind a cancer related antigen |
WO1999038500A2 (en) * | 1998-01-30 | 1999-08-05 | The Brigham And Women's Hospital, Inc. | The human calcium-sensing receptor in the detection and treatment of cancer |
US5935798A (en) * | 1993-07-09 | 1999-08-10 | The Regents Of The University Of California | Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices |
WO2002059377A2 (en) * | 2001-01-24 | 2002-08-01 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
WO2003050307A1 (en) * | 2001-12-05 | 2003-06-19 | Genzyme Corporation | Compounds for therapy and diagnosis and methods for using same |
WO2003054165A2 (en) * | 2001-12-20 | 2003-07-03 | The Regents Of The University Of California | Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis |
US20030175855A1 (en) * | 1997-02-06 | 2003-09-18 | Lavallie Edward R. | Human sdf-5 protein and compositions |
WO2003083141A1 (en) * | 2002-03-29 | 2003-10-09 | Arcturus Engineering, Inc. | Interpreting cytological specimens via molecular histological signatures |
US20040086504A1 (en) * | 2001-06-21 | 2004-05-06 | Deepak Sampath | Cyr61 as a target for treatment and diagnosis of breast cancer |
EP1435243A2 (en) * | 1998-11-13 | 2004-07-07 | Curis, Inc. | Methods of alleviating cancer symtoms |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
-
2005
- 2005-07-27 DK DK05763127.7T patent/DK1781814T3/en active
- 2005-07-27 CA CA002576113A patent/CA2576113A1/en not_active Abandoned
- 2005-07-27 EP EP05763127A patent/EP1781814B3/en not_active Not-in-force
- 2005-07-27 AT AT05763127T patent/ATE454474T1/en not_active IP Right Cessation
- 2005-07-27 JP JP2007525333A patent/JP5117852B2/en not_active Expired - Fee Related
- 2005-07-27 MX MX2007001640A patent/MX2007001640A/en active IP Right Grant
- 2005-07-27 DE DE602005018789T patent/DE602005018789D1/en active Active
- 2005-07-27 WO PCT/GB2005/002971 patent/WO2006016110A1/en active Application Filing
- 2005-07-27 PT PT05763127T patent/PT1781814E/en unknown
- 2005-07-27 ES ES05763127T patent/ES2339132T7/en active Active
- 2005-07-27 CN CN201110315370.0A patent/CN102443627B/en not_active Expired - Fee Related
- 2005-07-27 US US11/573,487 patent/US20100035240A1/en not_active Abandoned
- 2005-07-27 AU AU2005271113A patent/AU2005271113B2/en not_active Ceased
-
2007
- 2007-01-30 GB GB0701676A patent/GB2430741A/en not_active Withdrawn
- 2007-10-12 HK HK07111076.7A patent/HK1103422A1/en not_active IP Right Cessation
-
2011
- 2011-09-12 JP JP2011198276A patent/JP5634360B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5872217A (en) * | 1989-01-17 | 1999-02-16 | The Johns Hopkins University | Antibodies which specifically bind a cancer related antigen |
US5935798A (en) * | 1993-07-09 | 1999-08-10 | The Regents Of The University Of California | Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices |
US20030175855A1 (en) * | 1997-02-06 | 2003-09-18 | Lavallie Edward R. | Human sdf-5 protein and compositions |
WO1999038500A2 (en) * | 1998-01-30 | 1999-08-05 | The Brigham And Women's Hospital, Inc. | The human calcium-sensing receptor in the detection and treatment of cancer |
EP1435243A2 (en) * | 1998-11-13 | 2004-07-07 | Curis, Inc. | Methods of alleviating cancer symtoms |
WO2002059377A2 (en) * | 2001-01-24 | 2002-08-01 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
US20040086504A1 (en) * | 2001-06-21 | 2004-05-06 | Deepak Sampath | Cyr61 as a target for treatment and diagnosis of breast cancer |
WO2003050307A1 (en) * | 2001-12-05 | 2003-06-19 | Genzyme Corporation | Compounds for therapy and diagnosis and methods for using same |
WO2003054165A2 (en) * | 2001-12-20 | 2003-07-03 | The Regents Of The University Of California | Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis |
WO2003083141A1 (en) * | 2002-03-29 | 2003-10-09 | Arcturus Engineering, Inc. | Interpreting cytological specimens via molecular histological signatures |
Non-Patent Citations (40)
Title |
---|
ADEYINKA ADEWALE ET AL: "Analysis of gene expression in ductal carcinoma in situ of the breast.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. DEC 2002, vol. 8, no. 12, December 2002 (2002-12-01), pages 3788 - 3795, XP002383037, ISSN: 1078-0432 * |
ALPY FABIEN ET AL: "Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors.", ONCOGENE, vol. 22, no. 24, 12 June 2003 (2003-06-12), pages 3770 - 3780, XP002371737, ISSN: 0950-9232 * |
AL-RAWI M A A ET AL: "Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer.", EUROPEAN JOURNAL OF CANCER, vol. 40, no. 4, March 2004 (2004-03-01), pages 494 - 502, XP002383048, ISSN: 0959-8049 * |
ARIGA NAOHIRO ET AL: "Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast", INTERNATIONAL JOURNAL OF CANCER, vol. 95, no. 1, 20 January 2001 (2001-01-20), pages 67 - 72, XP002383041, ISSN: 0020-7136 * |
BERNAL JUAN A ET AL: "Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis", NATURE GENETICS, vol. 32, no. 2, October 2002 (2002-10-01), pages 306 - 311, XP002371740, ISSN: 1061-4036 * |
BJORNLAND KRISTIN ET AL: "Polymorphonuclear elastase in human colorectal carcinoma", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 12, no. 3, March 1998 (1998-03-01), pages 535 - 540, XP008064807, ISSN: 1019-6439 * |
BOURDON J -C ET AL: "Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane", JOURNAL OF CELL BIOLOGY, vol. 158, no. 2, 22 July 2002 (2002-07-22), pages 235 - 246, XP002371742, ISSN: 0021-9525 * |
CALLAHAN R ET AL: "NOTCH SIGNALING IN MAMMARY GLAND TUMORIGENESIS", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, PLENUM PRESS, NEW YORK, NY,, US, vol. 6, no. 1, January 2001 (2001-01-01), pages 23 - 36, XP001094918, ISSN: 1083-3021 * |
DAVIES GAYNOR ET AL: "Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer.", CLINICAL & EXPERIMENTAL METASTASIS. 2004, vol. 21, no. 1, 2004, pages 31 - 37, XP002371749, ISSN: 0262-0898 * |
DEBIES M T ET AL: "Genetic basis of human breast cancer metastasis.", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. OCT 2001, vol. 6, no. 4, October 2001 (2001-10-01), pages 441 - 451, XP002383042, ISSN: 1083-3021 * |
DECRISTOFARO M F ET AL: "Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.", JOURNAL OF CELLULAR PHYSIOLOGY. JAN 2001, vol. 186, no. 1, January 2001 (2001-01-01), pages 136 - 145, XP002383045, ISSN: 0021-9541 * |
DRESSMAN M A ET AL: "Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 9, 1 May 2003 (2003-05-01), pages 2194 - 2199, XP002317347, ISSN: 0008-5472 * |
FABRE STEPHANIE ET AL: "Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin4 bind to the predicted C-C'-C''-D beta-strands of the nectin1 V domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 30, 28 July 2002 (2002-07-28), pages 27006 - 27013, XP002371738, ISSN: 0021-9258 * |
FIRON MICHAL ET AL: "Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells", ONCOGENE, vol. 19, no. 20, 11 May 2000 (2000-05-11), pages 2386 - 2397, XP002371736, ISSN: 0950-9232 * |
FUNASAKA TATSUYOSHI ET AL: "Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 293, no. 1, 26 April 2002 (2002-04-26), pages 192 - 200, XP002383038, ISSN: 0006-291X * |
GOODISON STEVE ET AL: "The interrelationship between DRIM gene expression and cytogenetic and phenotypic characteristics in human breast tumor cell lines.", BMC GENOMICS, vol. 4, no. 39 Cited October 17, 2003, 22 September 2003 (2003-09-22), XP002383039, ISSN: 1471-2164 * |
JIANG WEN G ET AL: "Psoriasin is aberrantly expressed in human breast cancer and is related to clinical outcomes", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 25, no. 1, July 2004 (2004-07-01), pages 81 - 85, XP008061313, ISSN: 1019-6439 * |
KLEER CELINA G ET AL: "Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, no. 2, February 2002 (2002-02-01), pages 579 - 584, XP002371741, ISSN: 0002-9440 * |
LASTRAIOLI ELENA ET AL: "herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells.", CANCER RESEARCH, vol. 64, no. 2, 15 January 2004 (2004-01-15), pages 606 - 611, XP002383047, ISSN: 0008-5472 * |
LAUFFART BRENDA ET AL: "Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2.", GENOMICS, vol. 81, no. 2, February 2003 (2003-02-01), pages 192 - 201, XP002371748, ISSN: 0888-7543 * |
LEE BYEONG-CHEL ET AL: "Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells", MOLECULAR CANCER RESEARCH, vol. 2, no. 6, June 2004 (2004-06-01), pages 327 - 338, XP002371743, ISSN: 1541-7786 * |
LIN W ET AL: "Effects of a water-soluble antitumor ether phosphonoinositide, D-myo-inositol 4-(hexadecyloxy)-3(S)-methoxybutanephosphonate (C4-PI), on inositol lipid metabolism in breast epithelial cancer cell lines.", BIOCHEMICAL PHARMACOLOGY. 15 MAY 1999, vol. 57, no. 10, 15 May 1999 (1999-05-15), pages 1153 - 1158, XP002383043, ISSN: 0006-2952 * |
MOODY TERRY W ET AL: "VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.", LIFE SCIENCES, vol. 74, no. 11, 30 January 2004 (2004-01-30), pages 1345 - 1357, XP002383058, ISSN: 0024-3205 * |
MURPHY KELLEY: "Ubiquitin localization within cells in normal and cancer tissues.", FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03-01), & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; SAN DIEGO, CA, USA; APRIL 11-15, 2003, pages Abstract No. 723.6 URL - http://ww, XP008064812, ISSN: 0892-6638 * |
NISHIMURA YUKIO ET AL: "Overexpression of ROCK in human breast cancer cells: evidence that ROCK activity mediates intracellular membrane traffic of lysosomes.", PATHOLOGY ONCOLOGY RESEARCH : POR. 2003, vol. 9, no. 2, 2003, pages 83 - 95, XP002383044, ISSN: 1219-4956 * |
OKTAY MAJA H ET AL: "Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas.", HUMAN PATHOLOGY. MAR 2003, vol. 34, no. 3, March 2003 (2003-03-01), pages 240 - 245, XP002383040, ISSN: 0046-8177 * |
PARR CHRISTIAN ET AL: "The hepatocyte growth factor regulatory factors in human breast cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 JAN 2004, vol. 10, no. 1 Pt 1, 1 January 2004 (2004-01-01), pages 202 - 211, XP002371735, ISSN: 1078-0432 * |
ROSS J S ET AL: "Co-expression of matrilysin (MMP7) and stromelysin (MMPs3, 10, and 11) proteins and prognostic significance in mammary carcinomas", LABORATORY INVESTIGATION, vol. 82, no. 1, January 2002 (2002-01-01), & 2002 ANNUAL MEETING OF THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY; CHICAGO, IL, USA; FEBRUARY 23-MARCH 01, 2002, pages 50A, XP008061400, ISSN: 0023-6837 * |
SAAD Z ET AL: "Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 351, no. 9110, 18 April 1998 (1998-04-18), pages 1170 - 1173, XP004833240, ISSN: 0140-6736 * |
SAMPATH JANARDHAN ET AL: "SPF45, a novel spliceosome-associated protein is overexpressed in tumors", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 140, XP008061428, ISSN: 0197-016X * |
SCHULZ SOLVEIG ET AL: "True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5.", BREAST CANCER RESEARCH AND TREATMENT. APR 2002, vol. 72, no. 3, April 2002 (2002-04-01), pages 221 - 226, XP002371744, ISSN: 0167-6806 * |
SCHWEINFEST CLIFFORD W ET AL: "CaSm: An Sm-like protein that contributes to the transformed state in cancer cells", CANCER RESEARCH, vol. 57, no. 14, 1997, pages 2961 - 2965, XP002916655, ISSN: 0008-5472 * |
SCHWIRZKE MARINA ET AL: "Identification of metastasis-associated genes by transcriptional profiling of a pair of metastatic versus non-metastatic human mammary carcinoma cell lines", ANTICANCER RESEARCH, vol. 21, no. 3B, May 2001 (2001-05-01), pages 1771 - 1776, XP002967438, ISSN: 0250-7005 * |
SHEN TIANJIE ET AL: "Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294", MOLECULAR AND CELLULAR BIOLOGY, vol. 21, no. 18, September 2001 (2001-09-01), pages 6122 - 6131, XP002383055, ISSN: 0270-7306 * |
SPICER JAMES ET AL: "Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1.", ONCOGENE. 24 JUL 2003, vol. 22, no. 30, 24 July 2003 (2003-07-24), pages 4752 - 4756, XP002371739, ISSN: 0950-9232 * |
SUAREZ-CUERVO CATALINA ET AL: "Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells.", BREAST CANCER RESEARCH AND TREATMENT, vol. 80, no. 1, July 2003 (2003-07-01), pages 71 - 78, XP002383054, ISSN: 0167-6806 * |
SWISSHELM K ET AL: "SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily", GENE, ELSEVIER, AMSTERDAM, NL, vol. 226, no. 2, 21 January 1999 (1999-01-21), pages 285 - 295, XP004155143, ISSN: 0378-1119 * |
TSUTSUMI SOICHI ET AL: "Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts.", CANCER RESEARCH, vol. 63, no. 1, 1 January 2003 (2003-01-01), pages 242 - 249, XP002349071, ISSN: 0008-5472 * |
WAGSTAFF S C ET AL: "Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells", CARCINOGENESIS (OXFORD), vol. 21, no. 12, December 2000 (2000-12-01), pages 2175 - 2181, XP002383046, ISSN: 0143-3334 * |
WITTLIFF JAMES L: "Molecular signatures of endocrine responsive breast cancer using gene expression profiling.", JOURNAL OF CLINICAL LIGAND ASSAY, vol. 26, no. 1, April 2003 (2003-04-01), pages 45 - 49, XP008061401, ISSN: 1081-1672 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8497292B2 (en) | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
US10472677B2 (en) | 2005-12-28 | 2019-11-12 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
JP2009543044A (en) * | 2006-07-07 | 2009-12-03 | ヒュン−キ・キム | Breast cancer prognostic marker comprising HCCR-1 and obesity-inducing composition |
CN1919874B (en) * | 2006-09-18 | 2010-09-08 | 中国人民解放军军事医学科学院生物工程研究所 | Antibody molecule ATF-Fc fusion albumen of antiurokinase type fibrinolysin activator receptor and use thereof |
JP2010505123A (en) * | 2006-09-29 | 2010-02-18 | トランスレーショナル セラピューティクス,インク. | eIF4E regulon-based diagnostics |
WO2008138868A3 (en) * | 2007-05-09 | 2009-01-08 | Traslational Cancer Drugs Phar | In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression |
WO2008138868A2 (en) * | 2007-05-09 | 2008-11-20 | Traslational Cancer Drugs Pharma, S.L. | In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression |
WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
WO2008150512A3 (en) * | 2007-06-04 | 2009-04-30 | Univ Louisville Res Found | Methods for identifying an increased likelihood of recurrence of breast cancer |
US20100081666A1 (en) * | 2008-07-14 | 2010-04-01 | Wyeth | Src activation for determining cancer prognosis and as a target for cancer therapy |
US9394358B2 (en) | 2008-11-10 | 2016-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
WO2010054379A2 (en) * | 2008-11-10 | 2010-05-14 | The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
WO2010054379A3 (en) * | 2008-11-10 | 2010-09-30 | The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
US8735082B2 (en) | 2008-11-10 | 2014-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
WO2010063454A1 (en) * | 2008-12-01 | 2010-06-10 | University Of Ulster | Method of stratifying breast cancer patients based on gene expression |
US20120183543A1 (en) * | 2009-05-08 | 2012-07-19 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
EP2723924A4 (en) * | 2011-06-22 | 2015-03-25 | Oncocyte Corp | Methods and compositions for the treatment and diagnosis of cancer |
EP2723924A1 (en) * | 2011-06-22 | 2014-04-30 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
EP2751570A4 (en) * | 2011-08-31 | 2015-08-12 | Oncocyte Corp | Methods and compositions for the treatment and diagnosis of cancer |
WO2013110053A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
EP2804960A4 (en) * | 2012-01-20 | 2015-08-19 | Univ Ohio State | Breast cancer biomarker signatures for invasiveness and prognosis |
EP3093343A4 (en) * | 2014-01-10 | 2017-12-27 | Juntendo Educational Foundation | Method for assessing lymph node metastatic potential of endometrial cancer |
CN104725488A (en) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | Tight junction protein inhibitor polypeptide and application thereof |
CN104725487A (en) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | Tight junction protein inhibitor polypeptide and application thereof |
US10047155B2 (en) | 2015-06-05 | 2018-08-14 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor |
EP3321683A4 (en) * | 2015-07-09 | 2018-11-21 | Juntendo Educational Foundation | Method for evaluating lymph node metastatic potential of endometrial cancer |
CN108504726A (en) * | 2018-03-28 | 2018-09-07 | 华南农业大学 | The pretreated methods of PCR are carried out using AMF single spore minim DNAs |
CN108504726B (en) * | 2018-03-28 | 2021-10-26 | 华南农业大学 | Method for carrying out PCR pretreatment by adopting AMF single spore trace DNA |
WO2020008097A3 (en) * | 2018-07-03 | 2020-03-19 | Universidad De Granada | Method for obtaining data that can be used for the prediction or prognosis of overall survival and relapse-free survival from cancer, and composition that can modulate the activity of atf4 for the treatment of cancer |
CN109620832A (en) * | 2019-01-14 | 2019-04-16 | 大连大学 | Glycocholic acid is preparing the application in resisting hyperplasia of mammary glands drug |
CN109620832B (en) * | 2019-01-14 | 2021-01-01 | 大连大学 | Application of glycocholic acid in preparation of anti-hyperplasia of mammary glands medicine |
Also Published As
Publication number | Publication date |
---|---|
PT1781814E (en) | 2010-04-12 |
CN102443627B (en) | 2014-10-29 |
JP5117852B2 (en) | 2013-01-16 |
AU2005271113A1 (en) | 2006-02-16 |
AU2005271113B2 (en) | 2010-12-09 |
JP2012024095A (en) | 2012-02-09 |
CA2576113A1 (en) | 2006-02-16 |
EP1781814B3 (en) | 2011-08-31 |
GB2430741A (en) | 2007-04-04 |
DE602005018789D1 (en) | 2011-05-26 |
MX2007001640A (en) | 2007-07-25 |
EP1781814A1 (en) | 2007-05-09 |
HK1103422A1 (en) | 2007-12-21 |
DK1781814T3 (en) | 2010-05-03 |
JP2008508895A (en) | 2008-03-27 |
ATE454474T1 (en) | 2010-01-15 |
EP1781814B1 (en) | 2010-01-06 |
JP5634360B2 (en) | 2014-12-03 |
GB0701676D0 (en) | 2007-03-14 |
ES2339132T7 (en) | 2012-03-16 |
ES2339132T3 (en) | 2010-05-17 |
WO2006016110A8 (en) | 2006-08-24 |
CN102443627A (en) | 2012-05-09 |
US20100035240A1 (en) | 2010-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1781814B1 (en) | Methods and kit for the prognosis of breast cancer | |
JP6908571B2 (en) | Gene expression profile algorithms and tests to quantify the prognosis of prostate cancer | |
CN101014720B (en) | Methods and kit for the prognosis of breast cancer | |
RU2654587C2 (en) | Method for predicting breast cancer recurrent during endocrine treatment | |
ES2735993T3 (en) | Methods to predict the clinical outcome of cancer | |
JP4606879B2 (en) | Gene expression profiling of EGFR positive cancer | |
JP6743056B2 (en) | Prostate Cancer Prognosis Judgment Method | |
JP5951603B2 (en) | Diagnosis and treatment of breast cancer | |
IL243205A (en) | Method for using gene expression to determine prognosis of prostate cancer | |
EP2191020A2 (en) | Gene expression markers of recurrence risk in cancer patients after chemotherapy | |
US20120004127A1 (en) | Gene expression markers for colorectal cancer prognosis | |
US10233502B2 (en) | Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer | |
CN101400804A (en) | Gene expression markers for colorectal cancer prognosis | |
US11840733B2 (en) | Method for predicting prognosis of breast cancer patient | |
WO2019134994A1 (en) | Prognostic biomarkers for human papillomavirus positive cancers | |
US20200370122A1 (en) | Immune index methods for predicting breast cancer outcome | |
CN110656169A (en) | Diagnostic markers for atrial fibrillation | |
KR20200038045A (en) | Gene set for guiding surgical treatment in bladder cancer | |
KR20170095761A (en) | COMPOSITION FOR DIAGNOSING LEUKEMIA USING TMEM57 OR NudC |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 0701676.9 Country of ref document: GB Ref document number: 0701676 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: 958/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005763127 Country of ref document: EP Ref document number: 2005271113 Country of ref document: AU Ref document number: 2576113 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001640 Country of ref document: MX Ref document number: 2007525333 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005271113 Country of ref document: AU Date of ref document: 20050727 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005271113 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030372.8 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005763127 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11573487 Country of ref document: US |